2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.
Eileen M. O’Reilly, MD, associate director for Clinical Research, David M. Rubenstein Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer Center, discusses factors that patients and oncologists should consider when developing a treatment plan for pancreatic cancer.
Oncologists will often take into consideration patients’ preference with factors such ability to come in often for infusions, fear of alopecia, and costs of care, which is becoming increasingly prevalent in the conversation regarding treatment planning, O’Reilly says.
Comorbidities and performance status are also considered, and as more therapies for pancreatic become available, more oncologists are questioning whether second-line therapies should be considered when choosing the initial treatment.
<<<